[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621431":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":50,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","(levo-dopa group, n =30) who will receive levo-dopa\u002Fcarbidopa (125\u002F12.5) mg three times daily for 6 months.",[13],"Drug: L-dopa",{"label":15,"type":10,"description":16,"interventionNames":17},"Etoricoxib group","will receive levo-dopa\u002Fcarbidopa (125\u002F12.5) mg three times daily plus Etoricoxib 90 mg once daily",[13,18],"Drug: Etoricoxib",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","L-dopa","Levodopa is the standard therapy in PD.",[9,15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Etoricoxib","Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.",[15],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mansoura University","RECRUITING","Al Mansurah","26548","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.38069,31.03637,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Ehab Hassan, PhD","CONTACT","01067831661","Ehassan@horus.edu.eg",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Ihab Elsayed Hassan","Lecturer","100621431","phase-2-etoricoxib-in-patients-with-parkinsonian-disease-100621431",false,"NCT07370532","Etoricoxib in Patients With Parkinsonian Disease","Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both male and female will be included.\n* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.\n\nExclusion Criteria:\n\n* Breast feeding\n* Patients with significant liver and kidney function abnormalities.\n* Alcohol and \u002F or drug abusers.\n* Patients with known allergy to the study medications\n* Pregnant women and women with planned pregnancy.\n* Patients who are currently using other anti-inflammatory drugs.","ALL","50 Years","70 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).",[72],"Parkinson Disease","2026-04-02",{"date":75,"type":76},"2026-04-08","ACTUAL",{"date":78,"type":76},"2026-01-30",{"date":80,"type":66},"2027-11-20",{"name":52,"class":6},1]